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Case Series: Gene Expression
Analysis in Canine Vogt-Koyanagi-
Harada/Uveodermatologic Syndrome
and Vitiligo Reveals Conserved
Immunopathogenesis Pathways
Between Dog and Human
Autoimmune Pigmentary Disorders
Ista A. Egbeto1,2, Colton J. Garelli 1, Cesar Piedra-Mora3, Neil B. Wong1,
Clement N. David4, Nicholas A. Robinson3† and Jillian M. Richmond1*
1 Department of Dermatology, UMass Medical School, Worcester, MA, United States, 2 Tufts University School of Medicine,
Boston, MA, United States, 3 Pathology Department, Tufts Cummings School of Veterinary Medicine, Grafton, MA, United States,
4 Nanostring Technologies, Seattle, WA, United States
Vogt-Koyanagi-Harada syndrome (VKH) and vitiligo are autoimmune diseases that target
melanocytes. VKH affects several organs such as the skin, hair follicle, eyes, ears, and
meninges, whereas vitiligo is often limited to the skin and mucosa. Many studies have
identified immune genes, pathways and cells that drive the pathogeneses of VKH and
vitiligo, including interleukins, chemokines, cytotoxic T-cells, and other leukocytes. Here,
we present case studies of 2 canines with VKH and 1 with vitiligo, which occurred
spontaneously in client-owned companion dogs. We performed comparative
transcriptomics and immunohistochemistry studies on lesional skin biopsies from these
cases in order to determine if the immunopathogenesis of autoimmune responses against
melanocytes are conserved. In dogs, we found enrichment of T cell gene signatures, with
upregulation of IFNG, TNF, PRF1, IL15, CTSW, CXCL10, and CCL5 in both VKH and
vitiligo in dogs compared to healthy controls. Similar findings were reported in humans,
suggesting that these genes play a role in the pathogenesis of spontaneous VKH and
vitiligo. T cell-associated genes, including FOXP3 and TBX21, were enriched, while
IGFBP5, FOXO1, and PECAM1 were decreased compared to healthy controls. Further,
we identified TGFB3, SFRP2, and CXCL7 as additional potential drivers of autoimmune
pigmentary disorders. Future studies exploring the immunopathogenesis of spontaneous
autoimmunity will expand our understanding of these disorders, and will be useful in
developing targeted therapies, repurposing drugs for veterinary and human medicine, and
predicting disease prognosis and treatment response.
Keywords: vitiligo, Vogt-Koyanagi-Harada disease, immunopathogenesis, transcriptomics, comparative
immunology, canine (dog)
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INTRODUCTION
Autoimmune pigmentary disorders include vitiligo and Vogt-
Koyanagi-Harada (VKH) syndrome, which are caused by the
destruction of melanocytes (1, 2). These diseases are mediated by
T-cells that target melanocyte self-antigens, including tyrosinase,
tyrosinase-related proteins 1 & 2 (TRP1/2), gp100/Pmel-17, and
melan-a/MART-1 (3–9). Vitiligo is characterized by loss of
melanocytes in the skin and mucosa (1). VKH is more extensive
and includes the skin,mucosa, eyes, ears, andmeninges, resulting in
chronic uveitis, alopecia, vitiligo, poliosis, and irritation of the
meninges (10). The current hypothesis in the field is that VKH
represents an exacerbated reaction by melanocytes and their
precursors as compared to vitiligo.
VKH is usually manifested during the third decade of life and
is present in all ethnic groups across the world. The prevalence is
higher in groups with darker skin tones and in Asians (11). VKH
syndrome is thought to be associated with HLA-DRB1*0405
(12), and polymorphisms in immune genes (13). Patients often
present with bilateral uveitis that is often preceded by a mild
prodromal illness, along with auditory and neurological
symptoms. Isolated ocular involvement in the initial phases of
the disease is also common. The choroid is the primary site of
inflammation, with the iris and ciliary body also affected. VKH
syndrome is classified into three different categories:
1. Complete VKH- vitiligo is associated with complete VKH.
Manifestations of complete VKH includes diffuse choroiditis
affecting the eyes bilaterally and causing retinal detachments.
Other signs include tinnitus, alopecia, neck stiffness, poliosis,
and vitiligo.
2. Incomplete VKH- these patients present with similar ocular
symptoms as patients with complete VKH, but they do not
have both neurological and skin symptoms.
3. Probable VKH- these patients have similar ocular symptoms
as patients with VKH, and they tend to have neurologic and
auditory manifestations or dermatologic signs, but not both
(10).
Several cytokines and chemokines contribute to the development
of vitiligo andVKH, including type1 responses (IFNg,CXCL9/10/11,
IL-12,TNF) type 17 responses (IL-17,CCL20, IL-23) and IL-2,which
supports T cell growth and survival (13–19). Some studies have
demonstrated that patients with VKH that have vitiligo have a
predominance of CD4+ T-cell lymphocytes and an imbalanced
ratio of CD4+/CD8+ T-cells (10), though others have
demonstrated a CD8+ cytotoxic T cell preponderance (15). These
CD8+Tcells react tomelanocyteantigensandexhibitmarkersof skin
resident memory T cells (20, 21).
Vitiligo andVKH incanines share similar clinical characteristics
with human vitiligo and VKH [reviewed in (22)]. Dogs that have
VKHpresent similarly tohumanswith incompleteVKH,exhibiting
panuveitis and bilateral retinal detachment. Here, we analyzed
lesional skin tissue from two dogs with VKH and one dog with
vitiligo who presented to community veterinary clinics and were
biopsied for diagnostic purposes. We performed transcriptomic
and immunohistochemistry analysis on lesional skin tissue to
examine features of immunopathogenesis of pigmentary
disorders that are conserved during spontaneous disease in dogs
versus humans. Our findings support the IFNg-CXCR3 axis as a
prominent feature in canine autoimmune pigmentary disorders.




A 2.5-year-old male Bernese Mountain dog that presented with a 6-
month history of loss of pigmentation on his nose with periocular
erythema, seborrhea, and crusts around eyes, on the nose, back, and
tail. These symptoms were resolved with three months of steroid
therapy. Two punch biopsies were performed, and histopathology
revealed a lichenoid inflammation that multifocally obscured
the dermo-epidermal junction (interface inflammation). The
inflammation is predominantly composed of macrophages and
fewer lymphocytes and plasma cells. There was significant
pigmentary incontinence in the areas of inflammation with
macrophages containing fine, dust-like, granular melanin pigment.
The epidermis was moderately hyperplastic and hyperkeratotic. All
the above findings were consistent with VKH-like syndrome.
Case 2
A 4-year-old neutered male Siberian Husky dog that presented
with a 2-month history of changes of pigmentation and pruritus
of the nasal planum, muzzle, periocular skin, and oral mucous
membranes. The dog developed blepharospasm, iridal color
change, and pupillary miosis in the left eye. A punch biopsy in
this dog revealed similar histopathological findings as in case 1
that were all consistent with VKH-like syndrome.
Case 3
A 1.5-year-old, neutered male Rottweiler-Labrador mixed dog
presented with 1-month history of pigment changes of the nose
and haircoat. On physical examination the dog had bilaterally
symmetrical areas of leukotrichia interspersed with pigmented
(black) hair and no evidence of erythema, alopecia, or crusting.
Histopathology patchy and sharply demarcated loss of melanocytes
in the epidermis and follicular epithelium. Multifocally, the
epidermis and follicular epithelium, particularly in samples from
the planum nasale, there is a mild, perivascular lymphocytic
infiltrate with frequent migration of lymphocytes into the
epidermis. Some hair shafts contained minimal pigment. In light
of the clinical and histopathological findings, a diagnosis of vitiligo
was made.
RESULTS
Gene Expression Analysis From
Case Series Reveals Both New and
Previously Identified Genes Relevant
to Anti-Melanocyte Autoimmunity
RNA was extracted from two VKH cases, one vitiligo case, and
five healthy control leg margins and was analyzed with a custom
Egbeto et al. Transcriptomics of Canine VKH/Vitiligo
Frontiers in Immunology | www.frontiersin.org December 2020 | Volume 11 | Article 5905582
Nanostring probeset (H&E from cases presented in Figure 1A).
Agglomerative clustering of the entire 160 codeset revealed that
the three pigmentary disorder cases grouped together apart from
healthy controls (Figure S1). To understand the biology of VKH
and vitiligo in dogs, we performed more detailed analyses on
subsets of genes based on known cellular functions. First, we
examined genes related to skin and hair biology, as well as
neuroendocrine function in the skin (see Figure S2 for complete
gene set analyses). Tyrosinase (TYR) transcript was expressed in
the healthy controls and the vitiligo case, while the mean trended
lower in the VKH cases but showed no statistical difference from
controls (Figure 1B).IGFBP5, which is known to mediate fibrosis
(23), and FOXO1, which is associated with adipogenesis (24), were
significantly downregulated in lesional skin (Figure 1B). These
genes have not previously been associated with vitiligo or VKH, thus
their functions in disease warrant further investigation. TGFB3, a
growth factor and immune modulator, was significantly
upregulated in both VKH and vitiligo (Figure 1B). Profilaggrin
(gene name FLG), a protein hormone that promotes hair growth,
and SFRP2, a soluble regulator of WNT signaling, were significantly
upregulated in VKH but not vitiligo (Figure 1B). WNT signaling
has previously been reported to be disrupted in lesional vitiligo skin
(25), though its role in VKH is still unclear. Other skin-relevant
transcripts including involucrin (IVL), LORICRIN, EDA, EDAR,
KIT, WIF1, DNMT1, RXRG, VDR, TGFB1/2, and DCT showed
no statistical differences from controls (Figure S2). The
neuroendocrine gene CYP1B1 was significantly downregulated in
cases versus controls, though this contrasts with a previous report
describing upregulation in vitiligo blood samples (Dey-Rao and
Sinha 2017). KRT10, a marker of basal keratinocytes, was
significantly higher and PECAM1, a marker of endothelial cells,
was significantly lower in cases versus healthy controls, which may
reflect the site of biopsy (e.g. healthy leg margin versus nose for
cases; Figure S2).
Next, we used Nanostring Advanced Analysis software to
quantify cell types across our samples. We found that, similar to
humans (5, 26), T-cells are the predominant immune cells found
in VKH and vitiligo compared to healthy controls (Figures 2A, B).
We examined the T-cell-associated transcription factors FOXP3
and TBX21 (Tbet), which are the master regulators in Tregs and
Th1/Tc1 cells respectively, and found they were induced in VKH
and vitiligo compared to controls (Figure 2C). Th1 cells, cytotoxic
cells, exhausted CD8 T-cells and NK cells gene expression
signatures were increased in VKH and vitiligo compared to
healthy controls (Figure 2D). Neutrophil and B cell signatures
were also increased in lesional skin, whereas macrophage and
dendritic cells (DC) scores were equivalent across all 3 conditions.
However, there was an increase in CD103+ dermal DC scores,
which are known to cross-present antigens during antiviral and
anti-tumor immune responses (27, 28). The full analysis of the
canine immune cell panel genes is presented in Figure S3.
We next analyzed cytokines and chemokines. We found
statistically significant induction of IFNG, ISG15, TNF, IL12,
PRF1, and IL15 cytokine expression in dogs with VKH compared
A B
FIGURE 1 | Examination of histopathology, skin, and hair gene expression patterns in VKH and vitiligo in dogs reveals marked infiltration with changes in specific
genes. (A) Histopathologic examination of skin tissue samples. Hematoxylin and eosin (H&E) staining, magnifications 10x and 40x (scale bar = 300 microns 10x,
scale bar = 60 microns 40x). There is marked inflammation at the dermo-epidermal junction (interface dermatitis) in VKH (cases 1 and 2) and epidermal hyperplasia in
vitiligo (case 3), with pigment incontinence noted in all cases. (B) Relative mRNA expression of skin and hair-related gene transcripts in the cases compared to 5
healthy controls (leg margins). TGFB3, FLG, and SFRP2 were significantly increased, and TYR, IGFBP5, and FOXO1 were decreased; n = 2 VKH, 1 vitiligo, and 5
healthy controls; p values from two-tailed t tests healthy vs VKH: TYR p = 0.4466, IGFBP5 p = 0.0194, FOXO1 p = 0.0281, TGFB3 p = 0.0119, FLG p = 0.0009,
SFRP2 p = 0.0049.
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to healthy controls (Figure 3A). The vitiligo case exhibited even
higher ISG15 and PRF1, while IFNG, TNF, IL12, and IL15 levels
were closer to those in healthy controls. All of these genes have
been reported to be induced in immune-mediated pigmentary
disorders (21, 29–31). There was a trend towards increased
CD215, a receptor chain for IL15 that has previously been
shown to be upregulated on keratinocytes from lesional skin
(21), in the cases. IL21, which has previously been reported to be
upregulated in the Smyth chicken line, another model of
spontaneous vitiligo (32), was unchanged in our samples.
However, the IL21R was highly upregulated in lesional skin in
the VKH and vitiligo dogs. The full analyses of the immune
disease related genes, interferons and granzymes, and interleukins/
cytokines are presented in Figure S4.
Mouse and human studies have shown that the chemokines
CCL5 and CXCL10 are expressed in the skin during vitiligo (14,
15, 33, 34). We found significant upregulation of CCL5 and
CXCL10, as well as CXCL7 (gene name PPBP) in canine VKH
and vitiligo. CX3CL1 was significantly upregulated in VKH only,
and there was a similar, though not significant, trend in CXCL11
upregulation. CCL2 (Figure S3) and CXCL12 (Figure 3A) were
significantly downregulated in both conditions compared to
healthy controls. The full analysis of chemokine expression is





FIGURE 2 | Quantification of cell types and mRNA expression of T-cell-associated transcription factors FOXP3 and TBX21/Tbet reveals cytotoxic and Th1
responses. (A) Nanostring advanced cell type analysis heat map representing color-coded expression levels of differentially expressed genes from the indicated
leukocyte populations. Cases clustered together apart from healthy controls. (B) Bar plots of p-values for cell type enrichment analysis revealed that cytotoxic T-cells,
B-cells, and cytokines are the predominant cells in VKH samples. (C) FOXP3 and TBX21 were significantly increased in VKH samples as compared to healthy
controls; p values from two-tailed t tests FOXP3 p = 0.0004, TBX21 p = 0.0003. (D) Cell type scores from Nanostring advanced analysis demonstrating significant
increases in Th1 cells, cytotoxic cells, exhausted CD8s, NK CD56dim cells, B cells, and neutrophils in VKH cases. Macrophage and DC scores remained
unchanged, whereas dermal CD103+ dendritic cell scores were significantly increased as compared to healthy controls. n = 2 VKH, 1 vitiligo, and 5 healthy controls;
p values from two-tailed t tests: Th1 p = 0.0027, Cytotoxic p = 0.0005, exhausted CD8 p = 0.0076, NK CD56dim p = 0.0002, B cell p = 0.0034, neutrophil p = 0.0203,
macrophage p = 0.4838, DC p = 0.1095, dermal CD103+ DC p = 0.0768.
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IFNg and CXCL10 Protein Expression Are
Increased in Lesional Skin of VKH and
Vitiligo Compared to Healthy Controls
To confirm that IFNG and CXCL10, two well-characterized
drivers of anti-melanocyte responses, are expressed at the
protein level in lesional skin of VKH and vitiligo canines, we
performed immunohistochemistry. These cytokines were highly
expressed in tissue as compared to isotype and healthy controls,
with higher CXCL10 expression consistent with its role in
amplifying IFNg signals (Figure 3B). Taken together, these
results characterize immune and skin gene expression in
canine VKH and vitiligo, identify novel potential drivers of
disease, and reveal conserved immunopathogeneses between
human and canine spontaneous disease.
DISCUSSION
The pathogeneses of vitiligo and VKH are complex and not fully
defined. To better understand driving factors of the autoimmune
response in spontaneous autoimmune pigmentary disorders, we
performed this retrospective comparative immunology case
study to examine transcriptomics and immunohistochemistry
of many known, and several unknown, genes central to vitiligo
and VKH pathogeneses. In our study, we found increased T cell
responses, type 1 cytokines, chemokines, and memory T cell
responses in VKH dogs compared to healthy controls. These
genes have been established as drivers of human vitiligo
immunopathogenesis, particularly the IFNG cytokine signaling
pathway (29, 35, 36) and subsequent CXCR3 ligand expression
following activation of Janus Kinases (JAK) 1 and 2 (14, 37–40).
CCR5 and CXCR3 expressing leukocytes are recruited to the skin
following their ligands CCL5 and CXCL10, respectively (15, 33,
39). IL15 promotes development of skin resident memory T cells
(41), and a recent studies in a vitiligo mouse model and human
tissues revealed that the IL15 receptor is important for
autoimmune memory in vitiligo (21). Other groups have
reported that IL10, IL13, IL17A, and IL21 are increased in
vitiligo (42–45), though we did not observe this in our case
series study. Further, it is unclear if these cytokine profiles are
pertinent to specific clinical subtypes of disease, such as
inflammatory vitiligo, or if they are upregulated at specific
phases of disease or as a result of concurrent autoimmunity
or infections.
Like vitiligo, VKH appears to be driven by type 1 T cell
responses (46, 47), though eye involvement reveals Th17
signatures (48). CX3CL1 was upregulated specifically in VKH
skin in our case studies. Fractalkine has only been explored in
ocular disease, warranting further investigation in cutaneous
VKH, especially to understand differences in the biology versus
vitiligo (49).
We examined skin-specific genes that are associated with skin
and hair biology, including TYR, IGFBP5, FOXO1, FLG, WIF1,
and TGFB3. Of these genes, TGFB3 and FLG were found to be
significantly upregulated, whereas IGFBP5, FOXO1 and WIF1
A B
FIGURE 3 | Many cytokines and chemokines previously associated with human VKH and vitiligo are enriched in canine lesional skin. (A) Relative mRNA expression of
IFNG, ISG15, TNF, IL12, PRF1, IL15, IL21R, CXCL7, CXCL10, CCL5, and CX3CL1 were statistically significantly higher in VKH samples as compared to healthy controls.
CXCL12 mRNA expression was significantly lower in VKH samples compared to healthy controls, CD215 and CXCL11 were trending higher (though they did not reach
statistical significance), and IL21 was not significantly different. n = 2 VKH, 1 vitiligo, and 5 healthy controls; p values from two-tailed t tests healthy vs VKH: IFNG p =
0.0007, ISG15 p = 0.023, TNF p = 0.0073, IL12 p = 0.0107, PRF1 p = 0.0037, IL15 p = 0.0173, CD215 p = 0.0663, IL21 p = 0.8775, IL21R p < 0.0001, CXCL7 p =
0.0179, CXCL10 p = 0.0241, CXCL11 p = 0.1168, CCL5 p < 0.0001, CX3CL1 p = 0.0295, CXCL12 p = 0.0359. (B) Immunohistochemistry stains for IFN-g and
CXCL10 expression in lesional skin biopsies from dogs demonstrating increased protein levels in cases as compared to isotype and healthy controls (black scale bars =
300 microns 10x, grey scale bar = 150 microns 20x, black arrow case 3 indicates edge of lesion). n = 2 VKH, 1 vitiligo, and 5 healthy controls.
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were downregulated. In contrast to our findings of increased
TGFB3 ligand, polymorphisms in its receptor were not found to
be associated with VKH disease in a Chinese Han population (50).
The disparity in TGFB3 expression could be explained by
differences in dog versus human VKH, the stage at which the
skin biopsies have been studied, and/or differences in the biology
of the ligand versus the receptor. For example, TGFB3 (along with
IL10) is expressed in the resolution phase of VKH and may play a
relevant role in controlling the disease (51). The upregulation of
FLG in VKH and not in vitiligo was an unexpected finding. We
hypothesize that increased FLG expression in VKH dogs suggests
a process of chronic inflammation in hair follicles, which is lacking
in vitiligo. These differences may also be due to dog versus human
pathogenesis, or perhaps due to disease stage/duration.We suggest
further studies are needed to determine the roles of TGFB3 and
FLG in VKH and vitiligo.
IGFBP5, FOXO1, and WIF1 downregulation may indicate a
loss of tolerance mechanisms or melanocyte regenerative capacity
in the skin in canine VKH and vitiligo. IGFBP5 acts as a tumor
suppressor in human melanoma cells (52), which is interesting
given the hypothesis that vitiligo exists on an “immune spectrum”
with melanoma (53). FOXO1 represses TBX21-mediated effector
functions to promote memory CD8+ T cell formation and Treg
function; thus, a loss of FOXO1 may drive continued T cell
effector function in the skin during melanocyte autoimmunity
(54–56). WIF1 promotes melanogenesis in normal human
melanocytes (57), though it is not yet clear what impact a loss
of expression would have on vitiligo or VKH.
We also investigated genes involved in T-cell and Treg
regulation and function: PPARG, FOXO3A, TBX21, and
FOXP3. PPARG, which activates growth of melanocytes
through apoptosis (58) and promotes T cell differentiation and
survival (59, 60), was decreased in our cases compared to healthy
controls. FOXO3 is a transcription factor that is an important
regulator of the magnitude of CD8 T cell memory (61). FOXO3A
polymorphisms have been associated with oxidative stress and
altered Treg function in vitiligo patients (62, 63). Thus, decreases
in PPARG and FOXO3 may indicate reduced ability of Tregs to
function to suppress autoimmune responses of T cells against
melanocytes. FOXP3 and TBX21 were increased in our cases
compared to healthy controls, which correlates with data
revealing increased expression of these transcription factors in
VKH patients during an active uveitis episode (64). Together,
our data support enhanced effector T cell populations and
reduced Treg function present in the skin of canine vitiligo
and VKH patients.
TYR, which we hypothesized would be significantly
downregulated in VKH due to melanocyte loss, was not
statistically different from the healthy controls. Notably, a study
investigating tyrosinase gene family loci in VKH in Japanese
patients using single microsatellite marker analysis and
haplotype analysis did not find an association between TYR loci
and VKH syndrome (65). This suggests that perhaps immature
melanocytes or melanocyte precursors are preferentially targeted
in VKH. Vitiligo was found to be associated with the major alleles
of SNPs in the TYR region, particularly rs1393350 and the R402Q
SNP rs1126809 (66). This may suggest a difference in pathogenesis
between vitiligo and VKH involving tyrosinase as an autoantigen.
Our chemokine analysis revealed indicators of active, though
not very early, disease in the dogs as evidenced by high CCL5 and
FOXP3 (transiently upregulated in activated T-cells, allowing for
the development of peripheral/induced regulatory T-cells) and
low CXCL12 (67). We also identified PPBP/CXCL7 as a
significantly upregulated chemokine in the skin. CXCL7 was
previously reported to be upregulated in the serum of vitiligo
patients, though little is known about its role in skin homing,
warranting further study (68).
Our immune cell signature findings are strongly supported by
previous studies that vitiligo and VKH are mediated by T-cells,
particularly CD8 cytotoxic T-cells (69). Neutrophils are
understudied in the skin in vitiligo and VKH, in part because
they comprise a small fraction of the infiltrate and are not a
prominent component. The increase in neutrophils we observed
in these cases may be due to scratching behavior in the dogs,
which is known to induce neutrophil recruitment to the skin
(70). Nevertheless, blood neutrophils can contribute to ROS
generation (71) and were reported to be elevated in the
peripheral blood of patients with generalized vitiligo (72). We
also observed increased B-cell signatures. It has been reported
that in Akita dogs with VKH-like syndrome, cutaneous lesions
are mediated by T cells and macrophages and ocular lesions are
mediated primarily by B cells and macrophages (73).
Autoantibodies against melanocytes have been identified in
vitiligo and VKH, though it is still unclear if they are
biomarkers or drive pathogenesis (74, 75). In lupus, another
autoimmune disease, B cells have been postulated to serve as
antigen presenting cells (76). Future studies will need to be
conducted to determine the precise role of B cells and
neutrophils in vitiligo and VKH.
In contrast to increases in other immune cell signatures, we
found similar levels of macrophage and dendritic cell gene
signatures in lesional skin tissue. Previous studies have noted
the presence of macrophages in vitiligo lesions (6); thus a
limitation of our data is that we did not examine localization
of these cells within the tissue. It could be that, while total
numbers of antigen presenting cell populations remain largely
unchanged, that their localization within the tissue promotes
lymphoid aggregates.
Limitations in our study include the small sample of genes
analyzed (160 genes), and small sample size (we only had one
vitiligo dog sample, thus preventing us from including the
vitiligo sample in our statistical analyses). Due to the small
group size of our VKH sample data, the t tests we performed
may exhibit type I or type II errors which are dependent upon the
variance of gene expression data within the groups (77).
Nevertheless, several genes that we identified as differentially
expressed between healthy and VKH have been previously
published in human literature as DEGs for the condition.
Future studies would include a larger scale comparative
analyses and whole genome sequencing to better understand
the influence of genetic factors on the pathogenesis of VKH
disease and vitiligo.
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In summary, our data support the hypothesis that T cell
responses, type 1 cytokines, memory T cell responses, and
chemokines drive immunopathogenesis of spontaneous VKH
and vitiligo in both dogs and humans. Future studies expanding
our understanding of spontaneous autoimmunity will be useful
for providing a better understanding of autoimmune diseases
and will pave the way for drug repurposing in human and
veterinary medicine. For example, JAK inhibitors induce re-
pigmentation in patients with vitiligo (78–81). Oclacitinib, a
veterinary JAK inhibitor currently marketed for allergy and itch
relief (82–85), could potentially be repurposed to treat vitiligo
and VKH in dogs. Drugs that induce or worsen vitiligo could
serve as a novel therapeutic approach to melanoma. A canine
case report found a link between skin depigmentation and
toceranib phosphate, a tyrosine kinase inhibitor (86), and the
Flk-1 tyrosine kinase inhibitor SU5416 showed efficacy in phase
II clinical trials for advanced melanoma (87). Future studies
examining the mechanistic involvement of the gene targets we
have identified in our case series for treatment of autoimmune
pigmentary disorders or melanoma are warranted.
MATERIALS AND METHODS
Clinical Samples
Skin biopsies from the biorepository at Tufts Cummings School
(NR) were selected based on pathology reports and H&E sections
were reexamined by a board-certified veterinary pathologist to
confirm diagnoses and absence of obvious infectious disease.
Healthy control samples were obtained from leg margin biopsies
from amputations. Two VKH and one vitiligo biopsy sample
were obtained from shave and/or punch biopsies of male dogs as
noted in the case presentation section. Of note, vitiligo has equal
sex bias in dogs, whereas VKH is almost twice as likely to occur
in male dogs (22). Samples were deposited with written owner
consent in the Tufts biobank at the time the veterinary patients
were seen at the hospital, spanning the years 2011–2019.
Isolation of RNA From FFPE Blocks
30 µm curls were cut from the blocks and stored in Eppendorf
tubes at ambient temperature. RNA was isolated using the Qiagen
FFPE RNeasy kit per the manufacturer directions. Briefly, razor
blades were treated with RNase, excess paraffin was removed, and
tissues were sliced into thin strips (5 mm) to create more surface
area prior to incubation with deparaffinization solution (Qiagen).
The protocol was followed and RNA was quantified using
a nanodrop.
Nanostring Cartridge and Processing
A custom Nanostring canine gene panel of 160 genes including
cytokine, chemokine, and immune genes, as well as skin and
immune cell specific transcripts was created. We used B2M,
RPL13A, CCZ1, and HPRT as housekeeping genes for this study.
RNA was hybridized using a BioRad C1000 touch machine, and
samples were loaded into Nanostring cartridges and analyzed
with a Sprint machine. Gene expression data are deposited on
GEO under Accession # GSE154024.
nSolver Analysis
NanoString’s software, nSolverwasused for allNanoString analysis.
Raw counts were plotted with GraphPad Prism. Advanced analysis
was used for the “cell Type Score”, which is a summary statistic of
the expression of the marker genes for each cell type. It is the
geometric mean of the log2-transformed normalized counts for
each set ofmarker genes. These scores were validated against FACS
and IHC, and are a robust method of quantifying relative cell type
abundance (88).
IHC
IHC was performed on 5 µm sections using rabbit-anti-canine
CXCL10, IFNg (US Biological) or isotype control (Biolegend) at
1:100 dilution using a Dako automated slide staining machine.
All sections were counterstained with hematoxylin. H&E images
were taken using an Olympus BX51 microscope with Nikon NIS
Elements software version 3.10, and IHC images were taken
using an Olympus BX40 microscope with cellSens Entry software
version 1.14.
Statistics
To assess the statistical significance of our results, we performed
two-way ANOVA with Bonferroni posttests between healthy
controls and VKH cases on sets of defined genes (skin & hair,
neuroendocrine, immune disease related, interleukins/cytokines,
CC chemokines, CXC chemokines, immune cell panel genes, and
housekeeping genes) to observe obvious differences across the
dataset. We next performed two-tailed t-tests of VKH vs healthy
using GraphPad Prism software version 5 to examine potential
differences in previously identified genes pertinent to VKH
pathogenesis (De Winter 2013). A statistically significant
difference was considered as p <0.05.
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SUPPLEMENTARY FIGURE 1 | Heat map showing the expression patterns of
the 160 gene Nanostring panel in cases and healthy controls. Purple represents
upregulation and orange and yellow represent downregulation of gene expression.
Color density is associated with the level of gene expression. Dendrogram indicates
clustering/relatedness of samples, which segregated based on disease status.
SUPPLEMENTARY FIGURE 2 | Expression of skin, hair, and neuroendocrine
genes in VKH and vitiligo cases compared to healthy controls. The relative
expression of (A) highly expressed skin and hair genes, (B) lower level transcript
genes, and (C) neuroendocrine genes was evaluated by NanoString’s nSolver.
n = 2 VKH, 1 vitiligo, and 5 healthy controls; p values from two-way ANOVA with
Bonferroni post tests for healthy vs VKH: KRT10 p < 0.001, PECAM1 p < 0.001,
SFRP2 p < 0.01, IGFBP5 p < 0.001, CYP1B1 p < 0.001.
SUPPLEMENTARY FIGURE 3 | Expression of immune disease related genes in
the autoimmune pigmentary cases versus healthy controls. (A) Immune related
genes and (B) Interferons and granzymes expressed in skin. n = 2 VKH, 1 vitiligo,
and 5 healthy controls; p values from two-way ANOVA with Bonferroni post tests for
healthy vs VKH: SERPINB2 p < 0.05, VGLL3 p < 0.01, FAS p < 0.001, CTSW
p < 0.01.
SUPPLEMENTARY FIGURE 4 | Expression of interleukins/cytokines and
chemokines in cases versus healthy controls. (A) Interleukins/cytokines, (B) CC
chemokines, and (C) CXC chemokines in skin biopsies of VKH, vitiligo, and healthy
samples. n = 2 VKH, 1 vitiligo, and 5 healthy controls; p values from two-way
ANOVA with Bonferroni post tests for healthy vs VKH: IL6 p < 0.001, CCL2 p <
0.01, CCL5 p < 0.01, CXCL10 p < 0.01, CXCL14 p < 0.001.
SUPPLEMENTARY FIGURE 5 | Expression of canine immune cell genes and
housekeeping genes in cases versus healthy controls. (A) Highly expressed and
(B) lower expressed canine cell panel genes. (C)Housekeeping genes in biopsies from
cases and healthy controls. n = 2 VKH, 1 vitiligo, and 5 healthy controls; p values from
two-way ANOVA with Bonferroni post tests for healthy vs VKH: PECAM1 p < 0.01,
S100A12p<0.001, BLKp<0.01,CD244p<0.001, CD6p<0.001,CD84p<0.001,
GZMA p < 0.001, GZMB p < 0.001, IL21R p < 0.001, KLRD1 p < 0.001, KLRK1
p<0.001, SH2D1Ap<0.001, TBX21p<0.001, TNFRSF17p< 0.01, B2Mp<0.001.
REFERENCES
1. Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, Harris JE. New discoveries
in the pathogenesis and classification of vitiligo. J Am Acad Dermatol (2017)
77:1–13. doi: 10.1016/j.jaad.2016.10.048
2. Baltmr A, Lightman S, Tomkins-Netzer O. Vogt-Koyanagi-Harada syndrome -
current perspectives. Clin Ophthalmol (2016) 10:2345–61. doi: 10.2147/
OPTH.S94866
3. Palermo B, Campanelli R, Garbelli S, Mantovani S, Lantelme E, Brazzelli V, et al.
Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase
and gp100 in vitiligo by the use of major histocompatibility complex/peptide
tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo. J Invest
Dermatol (2001) 117:326–32. doi: 10.1046/j.1523-1747.2001.01408.x
4. Sugita S, Takase H, Taguchi C, Imai Y, Kamoi K, Kawaguchi T, et al. Ocular
infiltrating CD4+ T cells from patients with Vogt-Koyanagi-Harada disease
recognize human melanocyte antigens. Invest Ophthalmol Vis Sci (2006)
47:2547–54. doi: 10.1167/iovs.05-1547
5. van den Boorn JG, Konijnenberg D, Dellemijn TAM, van der Veen JP, Bos JD,
Melief CJM, et al. Autoimmune Destruction of Skin Melanocytes by
Perilesional T Cells from Vitiligo Patients. J Invest Dermatol (2009)
129:2220–32. doi: 10.1038/jid.2009.32
6. Le Poole IC, van den Wijngaard RM, Westerhof W, Das PK. Presence of T
cells and macrophages in inflammatory vitiligo skin parallels melanocyte
disappearance. Am J Pathol (1996) 148:1219–28.
7. Maezawa N, Yano A. Two distinct cytotoxic T lymphocyte subpopulations in
patientswithVogt-Koyanagi-Haradadisease that recognizehumanmelanomacells.
Microbiol Immunol (1984) 28:219–31. doi: 10.1111/j.1348-0421.1984.tb00673.x
8. Yamaki K, Gocho K, Hayakawa K, Kondo I, Sakuragi S. Tyrosinase family
proteins are antigens specific to Vogt-Koyanagi-Harada disease. J Immunol
(2000) 165:7323–9. doi: 10.4049/jimmunol.165.12.7323
9. Hayakawa K, Yamaki K, Takiyama N, Kotani T, Itoh N. Identification of Dog
VKH Disease and Experimental Model of VKH in Dog(2002). Available at:
https://iovs.arvojournals.org/article.aspx?articleid=2418842 (Accessed June
29, 2020).
10. Patil YB, Garg R, Rajguru JP, Sirsalmath M, Bevinakatti VA, Kumar M, et al.
Vogt-Koyanagi-Harada (VKH) syndrome: A new perspective for healthcare
professionals. J Family Med Prim Care (2020) 9:31–5. doi: 10.4103/
jfmpc.jfmpc_787_19
11. Lavezzo MM, Sakata VM, Morita C, Rodriguez EEC, Abdallah SF, da Silva
FTG, et al. Vogt-Koyanagi-Harada disease: review of a rare autoimmune
disease targeting antigens of melanocytes. Orphanet J Rare Dis (2016) 11:29.
doi: 10.1186/s13023-016-0412-4
12. Shindo Y, Inoko H, Yamamoto T, Ohno S. HLA-DRB1 typing of Vogt-
Koyanagi-Harada’s disease by PCR-RFLP and the strong association with
DRB1*0405 and DRB1*0410. Br J Ophthalmol (1994) 78:223–6. doi: 10.1136/
bjo.78.3.223
13. Ng JY, Luk FO, Lai TY, Pang C-P. Influence of molecular genetics in Vogt-
Koyanagi-Harada disease. J Ophthalmic Inflamm Infect (2014) 4:20.
doi: 10.1186/s12348-014-0020-1
14. Rashighi M, Agarwal P, Richmond JM, Harris TH, Dresser K, Su M-W, et al.
CXCL10 is critical for the progression and maintenance of depigmentation in
a mouse model of vitiligo. Sci Transl Med (2014) 6:223ra23–223ra23. doi:
10.1126/scitranslmed.3007811
15. Strassner JP, Rashighi M, Ahmed Refat M, Richmond JM, Harris JE. Suction
blistering the lesional skin of vitiligo patients reveals useful biomarkers of
disease activity. J Am Acad Dermatol (2017) 76:847–55.e5. doi: 10.1016/
j.jaad.2016.12.021
16. SushamaS,DixitN,GautamRK,AroraP,KhuranaA,AnubhutiA.Cytokineprofile
(IL-2, IL-6, IL-17, IL-22, and TNF-a) in vitiligo-New insight into pathogenesis of
disease. J Cosmet Dermatol (2019) 18:337–41. doi: 10.1111/jocd.12517
Egbeto et al. Transcriptomics of Canine VKH/Vitiligo
Frontiers in Immunology | www.frontiersin.org December 2020 | Volume 11 | Article 5905588
17. Gomes IA, de Carvalho FO, deMenezes AF, Almeida FM, ShanmugamS, de Souza
SiqueiraQuintans J, et al.Theroleof interleukins invitiligo: a systematic review. JEur
Acad Dermatol Venereol (2018) 32:2097–111. doi: 10.1111/jdv.15016
18. Singh S, Singh U, Pandey SS. Serum concentration of IL-6, IL-2, TNF-a, and
IFNg in Vitiligo patients. Indian J Dermatol (2012) 57:12–4. doi: 10.4103/
0019-5154.92668
19. Zhang L, Kang Y, Chen S, Wang L, Jiang M, Xiang L. Circulating CCL20: A
potential biomarker for active vitiligo together with the number of Th1/17
cells. J Dermatol Sci (2019) 93:92–100. doi: 10.1016/j.jdermsci.2018.12.005
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